Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Clinical Trial

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Comparative Study

Research Support, U.S. Gov't, P.H.S.

Clinical Trial, Phase II

Review

Case Reports

Multicenter Study

Publication Year

From

Quick links

Individual year

2023

2019

2017

2009

2007

2006

2004

2003

2002

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Fluvoxamine""[mesh_terms]

21 Results

Searching titles within these results

Relationship between fluvoxamine and stress barometer for nocturnal enuresis.

Osamu Arisaka, Kenichi Kano

Pediatrics international : official journal of the Japan Pediatric Society 2004;45(6):688-91

Full Text

Abstract

Delayed recurrent SIADH associated with SSRIs.

Irina I Krasnyansky, Yehoshua A Lehman, Zeev G Fidelman, Zeev H Arinzon

The Annals of pharmacotherapy 2002;36(7-8):1175-7

Full Text

Abstract

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.

Stephen Fowler, Elena Guerini, NaHong Qiu, Yumi Cleary, Neil Parrott, Gerard Greig, Navita L Mallalieu

The Journal of pharmacology and experimental therapeutics 2017;360(1):164-173

Full Text

Abstract

L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.

Shahin Akhondzadeh, Mehran Nematizadeh, Hossein Ghorbanzadeh, Hossein Sanjari Moghaddam, Mohammadreza Shalbafan, Mahsa Boroon, Amir-Abbas Keshavarz-Akhlaghi

Psychiatry and clinical neurosciences 2023;77(9):478-485

Free Full Text

Abstract

Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.

Akihiro Takano, Tetsuya Suhara, Tetsuya Ichimiya, Fumihiko Yasuno, Kazutoshi Suzuki

Journal of clinical psychopharmacology 2007;26(2):188-91

Full Text

Abstract

Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.

R M Moresco, C Colombo, F Fazio, A Bonfanti, G Lucignani, C Messa, C Gobbo, L Galli, A Del Sole, A Lucca, E Smeraldi

NeuroImage 2000;12(4):452-65

Full Text

Abstract

Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.

S K Sy, B K Tang, A Pastrakuljic, E A Roberts, W Kalow

European journal of clinical pharmacology 2002;57(5):377-86

Full Text

Abstract

Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.

S Tabrizian, H Peter, I Hand

International journal of psychiatry in medicine 2000;30(1):27-39

Full Text

Abstract

Fluvoxamine affects sildenafil kinetics and dynamics.

Christiane Hesse, Heike Siedler, Jürgen Burhenne, Klaus-Dieter Riedel, Walter E Haefeli

Journal of clinical psychopharmacology 2006;25(6):589-92

Full Text

Abstract

Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug.

Takashi Fukasawa, Norio Yasui-Furukori, Akihito Suzuki, Genki Ishii, Yoshimasa Inoue, Tomonori Tateishi, Koichi Otani

Therapeutic drug monitoring 2006;28(3):308-11

Full Text

Abstract

Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.

Y W Francis Lam, Cara L Alfaro, Larry Ereshefsky, Michael Miller

Journal of clinical pharmacology 2004;43(11):1274-82

Full Text

Abstract

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

Mong-Liang Lu, Hsien-Yuan Lane, Shih-Ku Lin, Kun-Po Chen, Wen-Ho Chang

The Journal of clinical psychiatry 2004;65(6):766-71

Full Text

Abstract

Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.

Gunnel Tybring, Leif Bertilsson, Rajaa A Mirghani, Orjan Ericsson, Lars L Gustafsson

European journal of clinical pharmacology 2003;59(1):23-8

Full Text

Abstract

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.

Yan Li, Liangang Liu, Xiaomin Wang, Chengyue Zhang, Josephine Reyes, Matthew Hoffmann, Maria Palmisano, Simon Zhou

Journal of clinical pharmacology 2019;58(10):1295-1304

Free Full Text

Abstract

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Magnus Christensen, Gunnel Tybring, Kazuo Mihara, Norio Yasui-Furokori, Juan Antonio Carrillo, Sara I Ramos, Katarina Andersson, Marja-Liisa Dahl, Leif Bertilsson

Clinical pharmacology and therapeutics 2002;71(3):141-52

Full Text

Abstract

Results: 1 – 15 / 21

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Fluvoxamine""[mesh_terms]

Relationship between fluvoxamine and stress barometer for nocturnal enuresis.

Delayed recurrent SIADH associated with SSRIs.

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.

L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.

Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.

Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.

Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.

Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.

Fluvoxamine affects sildenafil kinetics and dynamics.

Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug.

Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.

In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Results for
""Fluvoxamine""[mesh_terms]